Valeant sells iNova Pharmaceuticals to PEP, Carlyle for $930 million, subject to approvals
MLex Summary: NYSE-listed Valeant Pharmaceuticals International has agreed to sell its Australia-based iNova Pharmaceuticals business to a company jointly owned by funds advised and managed by Australasian firm Pacific Equity Partners...To view the full article, register now.
Already a subscriber? Click here to view full article